Transition Therapeutics Inc (TTH.TO)

TTH.TO

About

Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company’s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer’s disease and bipolar disorder; TT-401/402 for the treatment of... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.39
Market Cap (Mil.):	$80.76
Shares Outstanding (Mil.):	26.92
Dividend:	--
Yield (%):	--

Financials

	TTH.TO	Industry	Sector
P/E (TTM):	--	35.67	35.85
EPS (TTM):	-0.02	--	--
ROI:	-1.61	19.40	18.76
ROE:	-1.67	20.11	19.57

Latest News about TTH.TO

Transition shares soar on positive diabetes drug results

- Transition Therapeutics Inc said an early-stage study of its experimental drug for type 2 diabetes showed significant improvement in blood sugar control and reduction in body weight, sending its shares up as much as 71 percent.

30 Apr 2013

» More TTH.TO News

Competitors

	Price	Change
Lexicon Pharmaceuticals, Inc. (LXRX.OQ)	$2.18	-0.03
StemCells Inc (STEM.OQ)	$1.86	-0.04
Theratechnologies Inc (TH.TO)	$0.25	-0.00

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - TRANSITION THERAPEUTICS, INC. (TTH-T) Provider: Thomson Reuters Stock Report	$25.00 Buy
Wright Investors Service Comprehensive Report for Transition Therapeutics, Inc. Provider: Wright Reports	$460.00 Buy
TRANSITION THERAPEUTICS INC CA (TTHI) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
Transition Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Transition Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.